RSNA 2024

MRI shows immediate impact of vaping, cigarette use
By Amerigo Allegretto
MRI shows that vaping has immediate negative effects on vascular function.
November 25, 2024
Cuff occlusion paradigm shows the following: (a) Cross-sectional images of the femoral artery that were used to draw regions of interest before (rest) and after cuff occlusion (at three different time points) to determine flow mediated dilation; (b) Femoral vein oxygen saturation (SvO2) plotted vs time after cuff release. SvO2 is derived from the difference between venous and arterial signal phase. (Tw = washout time); and (c) Average blood flow velocity-time curve in the femoral artery. (HI = hyperemic index; Vp = peak velocity; Tp = time to peak velocity; TFF = time of forward flow)
Thyroid medication linked to bone loss
By Will Morton
Levothyroxine – a common medication taken for hypothyroidism – may be associated over time with bone loss.
November 25, 2024
Levothyroxine pills. Image courtesy of RSNA.
Road to RSNA 2024: Molecular Imaging Preview
By Will Morton
Theranostics could be cited for speeding in this year’s Road to RSNA. It's only been a few years since a dedicated track in nuclear medicine and molecular imaging was established at the meeting, and the practice already dominates it.
November 21, 2024
Road To Rsna
FAPI-PET/CT superior to FDG-PET/CT in liver cancer patients
By Will Morton
Ga-68 FAPI-PET/CT imaging appears superior to FDG-PET/CT for assessing hepatocellular carcinomas. In a large prospective trial, the approach was more accurate – enough so that it could possibly replace FDG-PET/CT in the future.
November 21, 2024
FAPI-PET/CT improves detection of primary and metastatic breast cancer
By Will Morton
Ga-68 FAPI-PET/CT significantly enhances the detection rate and staging of primary and metastatic breast cancer, demonstrating superior sensitivity and specificity compared with F-18 FDG-PET/CT.
November 21, 2024
Theranostics cost-effective in men with mCRPC
By Will Morton
Using theranostic radionuclides such as Ra-223 or Lu-177 to treat men with metastatic castration-resistant prostate cancer (mCRPC) is more cost-effective in the long term than traditional chemotherapy and radiotherapy, suggests a study in this session.
November 21, 2024
Additional Coverage
2023
2022
2021
2020
2019
Treatment-related factors enhance PSMA expression
By Will Morton
Certain prostate cancer features on PSMA-PET may be useful in selecting candidates who are more likely to respond to Lu-177 PSMA-617, according to a presentation in this session.
November 21, 2024
F-18 PSMA-DCFPyL and Ga-68 PSMA-11 deemed equivalent
By Will Morton
PET radiopharmaceuticals F-18 PSMA-DCFPyL and a Ga-68 PSMA-11 appear equivalent for determining patient eligibility for prostate cancer treatment with Lu-177 PSMA-617, researchers say.
November 21, 2024
AI segments lesions on Ga-68 DOTATATE PET/CT images
By Will Morton
In this session, researchers will present an automated deep-learning AI model that could help clinicians segment rare neuroendocrine tumors on whole-body 3D gallium-68 (Ga-68) DOTATATE PET/CT images.
November 21, 2024
Are Lu-177 PSMA-617 outcomes applicable in a community setting?
By Will Morton
During this session on theranostics, a study suggests that targeted education is needed to support the delivery of Lu-177 PSMA-617 to patients.
November 21, 2024
FES-PET shows promise for staging invasive lobular carcinoma
By Will Morton
A mid-study analysis presented during this session suggests that F-18 fluoroestradiol (FES) PET/CT may detect unsuspected stage IV invasive lobular carcinoma.
November 21, 2024
Dedicated brain PET system shows promise in Alzheimer’s disease imaging
By Will Morton
A high-resolution dedicated brain PET system could augment visual reading in the early diagnosis of dementia, suggests a study in this session.
November 21, 2024
Page 1 of 9
Next Page